Skip to main content
. 2018 Sep 26;12(1):36–42. doi: 10.1016/j.tranon.2018.09.004

Figure 4.

Figure 4

Overall and progression free survival of patients with VSCC in relation to HPV status and SLPI expression.

In Figure 4A and B, PFS and in Figure 4C and D OS is shown. PFS for HPV-negative patients (n = 89) was 72.4%, 71.1 and 59.3 after 3, 5, and 10 years respectively. HPV-positive patients (n = 10) showed 88.9% survival after 3 and 5 years. OS of the HPV-negative patients (n = 89) was 78.4%, 71.1% and 55.8% after 3, 5, and 10 years respectively and for the HPV-positive patients (n = 10) OS was 80% both after 3 and 5 years.

For Kaplan–Meier analysis SPLI expression of tumors with negative and weak expression (n = 56) and for tumors with moderate and strong expression (n = 43) was pooled. Patients with negative/weak expression showed 78.0% PSF after 3 and 5 years and of 68.9% after 10 years, while patients with moderate/strong SLPI tumor expression showed 69.0% after 3 years, 66.5% after 5 years and 52.5% PFS after 10 years (P = .044). OS of patients with negative/ weak and moderate/strong SLPI expression was not significantly different (P = .502), with OS in patients with negative/ weak SLPI expression being 78.6% after 3 years, 71.2% after 5 years and 52.0% after 10 years. OS of the patients with moderate/strong expression was 78.7%, 73.7% and 60.2% after 3, 5, and 10 years respectively.